{
  "pmcid": "12076147",
  "sha256": "1da01f875640c8312d37497158a7ce2f81db49109b3d57f4bbb78b2fad7def6f",
  "timestamp_utc": "2025-11-09T22:14:29.604669+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.046900406504065,
    "reading_ease": 28.907423780487818,
    "word_count": 246
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Sentinel Lymph Node Biopsy Omission in Breast Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to BCS with or without SLNB."
      },
      "Participants": {
        "score": 2,
        "evidence": "A total of 1733 women with unilateral cT1–2 N0 invasive breast cancer were recruited from multiple centers in the Netherlands."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to BCS with or without SLNB."
      },
      "Objective": {
        "score": 1,
        "evidence": "This non-inferiority randomised controlled trial (BOOG 2013-08) evaluates the oncological safety and impact on health-related quality of life (HRQoL) of omitting sentinel lymph node biopsy (SLNB)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was patient-reported arm function and HRQoL, assessed up to 3 years post-inclusion."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 1733 women with unilateral cT1–2 N0 invasive breast cancer were recruited from multiple centers in the Netherlands between May 2015 and January 2022."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "821 were analysed (392 with SLNB, 429 without SLNB) using an as-treated approach."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The SLNB group experienced a slight, temporary decline in arm function (P < 0.025) and more HRQoL arm and breast symptoms (P < 0.049)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02271828."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the Netherlands Cancer Institute."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}